The human aryl hydrocarbon receptor (hAHR) and mouse aryl hydrocarbon receptor (mAHR b ) share limited (58%) transactivation domain (TAD) sequence identity. Compared to the mAHR b allele, the hAHR displays 10-fold lower relative affinity for prototypical ligands, such as 2,3,7,8 tetrachlorodibenzo-p-dioxin (TCDD). However, in previous studies, we have demonstrated that the hAHR can display a higher relative ligand-binding affinity than the mAHR b for specific AHR ligands, such as indirubin. Each receptor has also been shown to differentially recruit LXXLL coactivator motif proteins and to utilize different TAD subdomains in gene transactivation. Using hepatocytes isolated from C57BL/6J mice (Ahr b/b ) and AHR Ttr transgenic mice, which express hAHR protein specifically in hepatocytes, we investigated whether the hAHR and mAHR b differentially regulate genes. DNA microarray and quantitative PCR analysis of Ahr b/b and AHR Ttr primary mouse hepatocytes treated with 10nM TCDD revealed that a number of established AHR target genes such as Cyp1a1 and Cyp1b1 are significantly induced by both receptors. Remarkably, of the 1752 genes induced by mAHR b and 1186 genes induced by hAHR, only 265 genes (~18%) were significantly activated by both receptors in response to TCDD. Conversely, of the 1100 and 779 genes significantly repressed in mAHR b and hAHR hepatocytes, respectively, only 462 (~49%) genes were significantly repressed by both receptors in response to TCDD treatment. Genes identified as differentially expressed are known to be involved in a number of biological pathways, including cell proliferation and inflammatory response, which suggest that compared to the mAHR b , the hAHR may play contrasting roles in TCDD-induced toxicity and endogenous AHR-mediated gene regulation.
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The aryl hydrocarbon receptor (AHR) is a ligand-activated basic helix-loop-helix Per-Arnt-Sim protein transcription factor (Okey et al., 1979; Poland and Knutson, 1982; Poland et al., 1987; Swanson and Bradfield, 1993) . The AHR can be activated by a diverse array of compounds including planar polycyclic aromatic hydrocarbons (PAHs) such as benzo[a]-pyrene, halogenated PAHs such as 2, 3, 7, , and a number of naturally occurring flavonols such as quercetin (2-(3,4dihydroxy-phenyl)-3,5,7-trihydroxy-4H-chromen-4-one) and plant tryptophan metabolites such as indirubin ((2Z) 2,3-biindole-2,3 (1'H,1'H)-dione (Ciolino et al., 1999; Guengerich et al., 2004) . In the cytoplasm, the AHR is part of a stable cytoplasmic multiprotein complex that consists of the hepatitis B virus X-associated protein 2 (XAP2/AIP/ARA 9), p23, and two molecules of heat-shock protein 90. Ligand activation of the AHR causes it to translocate into the nucleus, dissociate from its cytoplasmic complex, and heterodimerize with the aryl hydrocarbon receptor nuclear translocator (ARNT) (Ma et al., 1995) . This AHR/ARNT heterodimer then binds directly to dioxin-responsive elements (DREs/XREs) of dioxinresponsive genes, such as Cyp1a1, Cyp1B1, or Cyp1a2. Activated AHR can also interact with a number of other receptors and transcription factors such as the estrogen receptor and nuclear factor-kappa-light-chain-enhancer of activated Bcells to modulate gene expression (Kharat and Saatcioglu, 1996; Kim et al., 2000; Patel et al., 2009; Vogel and Matsumura, 2009) .
The degree and range of symptoms accompanying TCDD exposure drastically vary from one species to another and are probably partly due to interspecies differences in AHR structure. For example, guinea pigs are 1000-fold less sensitive to TCDDinduced toxicity than the sensitive hamster (Pohjanvirta et al., 1993) , both of which express AHR proteins that are structurally divergent at the N-and C-terminal domains (Henck et al., 1981) . In mice, TCDD exposure can result in immunotoxicity, developmental defects, reproductive toxicity, and both skin and liver cancers. TCDD is nongenotoxic and thus acts as a liver tumor promoter possibly through prolonged and inappropriate activation of AHR-regulated genes, such as interleukins (IL), proto-oncogenes, and inflammatory factors (Birnbaum, 1994; Silbergeld and Gasiewicz, 1989; Sutter et al., 1991; Watson et al., 1995) . Conversely, human exposure to TCDD has only been shown to cause chloracne (Denison et al., 1986) . Nonetheless, the Environmental Protection Agency classifies TCDD as a human carcinogen (Travis and Hattemer-Frey, 1991) .
Among inbred mouse strains that express the low ligandbinding affinity mouse aryl hydrocarbon receptor (mAHR) d (e.g., DBA) and the high ligand-binding affinity mAHR b (e.g., C57BL/6J) alleles, there is a marked difference in TCDD sensitivity with C57BL/6J mice displaying a relatively higher sensitivity to TCDD treatment (Ema et al., 1994; Poland and Glover, 1990; Poland et al., 1994; Weber et al., 1995) . The resistance to TCDD toxicity displayed by DBA mice is apparently due to expression of the mAHR d allele, which contains an alanine to valine (A375V) amino acid substitution in the ligand-binding domain of the mAHR d that sterically impinges on the binding of typical AHR ligands, such as TCDD (Ema et al., 1994; Poland et al., 1994) . Interestingly, this low-affinity mAHR d , V375 corresponding to V381, is conserved in the ligand-binding domain of the human aryl hydrocarbon receptor (hAHR), giving the hAHR a 10-fold lower relative affinity for TCDD when compared to the mAHR b (Ema et al., 1994; Ramadoss and Perdew, 2004) . However, recent investigations have demonstrated that the hAHR may actually display selectivity for structurally atypical ligands, including indirubin and quercetin ). This discovery suggested that the hAHR may be regulated by endogenous and exogenous ligand(s) that may be structurally different from typical highaffinity AHR ligands. This also may lend an evolutionary basis for the apparent resistance that humans display to dioxin toxicity.
There is a high degree of divergence that exists between the hAHR and mAHR b C-terminal domain structures. The C-terminal domains of both receptors, which encompass the receptor transactivation domains (TADs), share only a 58% amino acid sequence identity. This amino acid sequence disparity was shown to result in differential recruitment of LXXLL coactivator-binding motifs (Flaveny et al., 2008) . This finding suggests that the receptors may also differentially recruit coactivator/corepressor complexes and thus may differentially regulate gene expression following ligand activation. We decided to investigate whether the differences between the mAHR b and hAHR result in differences in receptor-regulated gene modulation in response to TCDD treatment. Toward this end, hepatocytes isolated from the hepatocyte-specific transgenic hAHR and C57BL/6J mice, which express mAHR b , were treated with TCDD or vehicle control. Total RNA from these cells was subjected to DNA microarray analysis to determine if each receptor was capable of differentially regulating gene expression. This study demonstrates that, in response to TCDD, the hAHR regulates a functionally different subset of genes compared to the mAHR b . Consequently, the accuracy of assessing human risk based on data obtained in rodent models may be confounded. Alb with transgenic hAHR expression mice derived on a fully inbred C57BL/6J background and so the AHR Ttr mice were therefore backcrossed to an eighth generation. These mice expressed hAHR protein specifically in hepatocytes under the control of the transthyretin promoter as described previously . All mice were genotyped using the relevant primers listed in Supplementary table 1 and as described previously Walisser et al., 2005) .
MATERIALS AND METHODS

Cytosol Preparation
Mouse livers were homogenized in MENG buffer (25mM 3-(Nmorpholino) propanesulfonic acid, 2mM ethylenediamenetetraacetic acid, 0.02% NaN 3 , 10% glycerol, pH 7.4) containing 20mM sodium molybdate and protease inhibitors (Sigma) and centrifuged at 100,000 3 g for 1 h.
Immunoblotting
Whole mouse liver cytosol was resolved using 8% SDS-tricine polyacrylamide gels. Proteins were transferred to polyvinyldene fluoride membrane, and AHR or b-actin proteins were detected using the mouse monoclonal antibodies RPT1 (Affinity BioReagents) or sc47778 (Santa Cruz Biotechnology Inc.) and visualized using autoradiography.
Primary Hepatocyte Isolation
Hepatocytes were isolated as described previously (Madden et al., 2000) , with a few modifications. Briefly, mice were anaesthetized with 0.1-0.3 ml 2.5% Avertin, administered via ip injection. Hepatic perfusion was performed with Buffer-I (5mM dextrose/116mM NaCl/760lM NaH 2 PO 4 /5.3mM KCl/26mM NaHCO 3 /10mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid/500lM ethylene glycol tetraacetic acid, pH 7.2) for 1 min, followed by Buffer-II (0.2 mg/ml type-I collagenase [Worthington]/5.3mM KCl/116mM NaCl/5mM dextrose/26mM NaHCO 3 /1.6mM MgSO 4 /900lM CaCl 2 /48 lg/ml trypsin inhibitor, pH 7.2) for a further 5-10 min. Hepatic tissue was excised, transferred, and dissociated in a 100-mm plate containing 9-ml short-term media (Dulbecco's Modified Eagles Medium/10% fetal bovine serum/2.5% dimethyl sulfoxide (DMSO)/10nM dexamethasone/100 IU/ml penicillin/100 lg/ ml streptomycin). Cells were filtered, centrifuged (500 3 g for 1 min), and resuspended in short-term media. Cell viability was assessed via trypan blue staining, and cells were seeded into type-I collagen-coated six-well plates (BD Bioscience) at a density of 1 3 10 6 cells/ml. After 4 h incubation at 37°C, nonadherent cells were aspirated and fresh short-term media added. After overnight incubation at 37°C, cells were washed with PBS and short-term media replaced with long-term hepatocyte culture media (Hepatozyme-SFM [Invitrogen]/2.5% DMSO/10nM dexamethasone/100 IU/ml penicillin/100 lg/ ml streptomycin). Hepatocytes were cultured in long-term media under standard conditions in a 37°C incubator at 5% CO 2 , 95% air, and cell culture media was changed every 48 h. DNA microarray analysis: isolation and labeling of RNA. Primary hepatocytes were isolated from six AHR Ttr mice and six Ahr b/b mice, respectively. After being cultured for 48 h, hAHR-and mAHR b -expressing hepatocytes were treated with 10nM TCDD or vehicle for 6 h. Total RNA isolated from primary hepatocytes was converted to complementary DNA (cDNA) and subjected to real-time reverse transcriptase (RT)-PCR to assess the degree of induction of AHR-responsive genes. RNA isolated using Tri-reagent (as described before) was additionally purified using RNeasy minicolumns (Qiagen). The quality of the RNA was assessed using formaldehyde agarose gels and a Bioanalyzer and RNA LabChip (Agilent Technologies) at the Penn State DNA microarray facility. Poly-A 218 FLAVENY, MURRAY, AND PERDEW (Affymetrix, Santa Clara, CA) controls were added to the RNA samples before they were labeled using GeneChip One-Cycle Target Labeling and Control Reagents (Affymetrix). Labeled samples were subsequently assessed for quality using RNA LabChip kit and Bioanalyzer to determine if minimal fragmentation was obtained. The quality of the samples was further tested using GeneChip Test 3 arrays that possess known mouse and human housekeeping gene sets. The labeled RNA used in each array was representative of hepatocytes isolated from each individual mouse. Samples that satisfied the quality control assessments were then used for full-scale hybridization and scanning using Affymetrix mouse genomewide expression set 430 2.0 arrays, which has 45,000 probe sets that analyze the expression levels of 39,000 transcripts over 34,000 well-characterized genes.
DNA microarray data analysis. GeneChip Operating Software (Affymetrix) was utilized to preprocess CAB/CEL files generated from the 12 scanned DNA microarrays, which represented hepatocytes isolated from one mouse each. Data quality was initially assessed by checking the array image, B2 oligo performance, average background to noise ratios, poly-A controls, hybridization controls, and the 3# to 5# probe set ratios for control genes (e.g., b-actin or GAPDH). DNA microarray data were normalized using Probe Logarithmic Intensity Error (PLIER-MM) approximation algorithm (Affymetrix Expression Console Software 1.1). Normalized DNA microarray data outputs from TCDD-and control-treated Ahr b/b and AHR Ttr hepatocytes were compared for differential expression using Significance Analysis of Microarrays (SAM, version 2.23A [Pan, 2002; Tusher et al., 2001] ) with 100 permutations, KNN-10. The total number of genes induced and repressed by the hAHR or mAHR b in response to TCDD was then calculated from the SAM output gene lists. For comparing TCDDand vehicle-treated sample arrays from either Ahr b/b or AHR Ttr hepatocyte expression value, comparisons were conducted at a value of 0.44 and a false discovery rate of 5%. Across the Ahr b/b or AHR Ttr hepatocyte genotypes, genes were considered significantly differentially induced or repressed in TCDD-treated Ahr b/b compared to TCDD-treated AHR Ttr primary hepatocytes based on a q value < 0.05. The ''q value'' is similar to a ''p value'' but is adapted to the analysis of a large number of genes and is a measure of significance in terms of the false discovery rate. Normalized array data files are available online at http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc¼ GSE17925. Differential expression of selected genes was validated using real-time RT-PCR.
Functional annotation cluster analysis of DNA microarray data. In order to identify the biological roles of the genes shown to be differentially regulated by the hAHR and mAHR b , the SAM output of differentially regulated genes was subjected to cluster analysis using the DAVID Functional Annotation Clustering Tool (Dennis et al., 2003; Huang da et al., 2009) (http://david.abcc.ncifcrf.gov/summary.jsp).
Real-time RT-PCR. Primary hepatocytes isolated from 8-to 10-week-old AHR Ttr , Ahr fx/fx Cre Alb , and Ahr b/b male mice were treated with 10nM TCDD or vehicle control for 6 h. For in vivo experiments, two groups of three 8-week-old male AHR Ttr , Ahr fx/fx /Cre Alb , and Ahr fx/fx mice were each treated via ip injection with 100 lg/kg TCDD or corn oil vehicle controls for 6 h. Total messenger RNA (mRNA) from whole-liver sections or primary hepatocytes was isolated using Tri-reagent (Invitrogen). RNA was then converted to cDNA using ABI cDNA archive synthesis kit (ABI), and mRNA expression was quantified using real-time RT-PCR (BioRad) and the relevant primers and normalized using control b-actin primers. All primer sequences are listed in Supplementary table 1. For all RT-PCR reactions, primer efficiencies were 100% (±10%) and melting curves were assessed to ensure that no nonspecific PCR products were formed or stable primer dimerization occurred. SD is represented by y-errors bars in all graphs shown.
Statistical analysis. Real-time RT-PCR data were analyzed using two-way ANOVA and Bonferroni posttests, and p values < 0.05 were considered statistically significant. (Fig. 1A) . Conversely, Ahr fx/fx mice exhibited a lower level of expression (Fig. 1A) . Ahr fx/fx , AHR Ttr , and Ahr fx/fx /Cre Alb mice were injected with 100 lg/kg TCDD or corn oil vehicle and assessed for expression of the AHRresponsive genes Cyp1a1, Cyp1a2, and Cyp1b1 using real-time RT-PCR. Ahr fx/fx mice express the low-affinity mAHR d allele, which has an affinity for TCDD that is comparable to that of the hAHR (Ramadoss and Perdew, 2004) . Both TCDD-treated AHR Ttr and Ahr fx/fx mice displayed similar levels of TCDDinduced expression of AHR-regulated genes (Fig. 1B) . /Cre Alb mice were treated with 10nM TCDD for 6 h. Total RNA, isolated from liver and hepatocytes, was converted to cDNA, and gene expression was quantified using real-time RT-PCR and primers for Cyp1a1, Cyp1a2, and Cyp1b1 (Supplementary table 1). *p < 0.05, **p < 0.01, ***p < 0.001.
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Interestingly, a small degree of constitutive expression of the AHR-regulated genes Cyp1a1 and Cyp1a2 was observed in liver samples from the control AHR Ttr mice, which was not seen in relevant samples from Ahr fx/fx mice (Fig. 1B) . Also, TCDDtreated Ahr fx/fx /Cre
Alb mouse livers exhibited a small degree of Cyp1a1, Cyp1a2, and Cyp1b1 activation, possibly due to the presence of other liver cell types that express mAHR. The degree of AHR induction as measured by Cyp1a1 activity was also similar between AHR Ttr and Ahr b/b hepatocytes treated with 10nM TCDD (Fig. 1C) . A dose of 10nM TCDD yielded a maximal level of Cyp1a1 mRNA induction as was previously determined in hepatocyte-based TCDD-induced dose-response experiments 
The mAHR b and hAHR Mutually Modulate a Limited Number of Genes in Primary Hepatocytes
The transcriptional profiles of vehicle-and TCDD-treated hepatocytes from AHR Ttr and Ahr b/b mice were assessed using Affymetrix mouse genome-wide expression set 430 2.0. Normalized array data from control and treated samples were then assessed for differential expression using SAM. The numbers of genes significantly induced or repressed were obtained from the SAM gene list outputs (Fig. 2) . The hAHR and mAHR b mutually induced 265 genes, which was onlỹ 15% of the total number of genes significantly induced by the mAHR b and~22% of the total number of genes significantly induced by the hAHR in response to TCDD (Fig. 2) . Interestingly, the hAHR and mAHR b also mutually repressed 462 genes that was~59% of the total number of genes repressed by the hAHR, while only~42% of the total number of genes were repressed by the mAHR b in response to TCDD (Fig. 2) . . Genes that were identified as differentially regulated were involved in a number of pathways. The pathways identified include immune function: IL10 and complement component 1, q subcomponent, alpha polypeptide (C1qa); cellular metabolism: acireductone dioxygenase 1 (Adi1) and insulin-degrading enzyme (Ide); and cell proliferation: epidermal growth factor (Egf) and gelsolin (Gsn) (Table 1, Fig. 4 ). Differentially expressed genes were subjected to cluster analysis using DAVID Functional Annotation Clustering Tool (Dennis et al., 2003; Huang da et al., 2009 ). Compared to the hAHR, the mAHR b was found to disproportionally regulate genes involved in metabolism and membrane transport in response to TCDD treatment. Conversely, the hAHR appeared to disproportionally regulate genes involved in immune response and cell proliferation compared to the mAHR b (Fig. 3 ).
hAHR and mAHR b Differentially Regulate the Genes Oxtr, Adi1, Egf, and Gsn in Primary Hepatocytes A number of genes identified as differentially expressed through DNA microarray analysis were selected and confirmed for differential regulation using real-time RT-PCR. Interestingly, oxytocin receptor (Oxtr), involved in the regulation of parturition and late-onset obesity, and acireductone dioxygenase 1 (Adi1), important to cellular recycling of methionine and mRNA processing, were differentially upregulated by the mAHR b in primary hepatocytes in response to TCDD treatment (Fig. 4A, Table 2 ). In contrast, epidermal growth factor (Egf), involved in the regulation of cellular differentiation and growth, and gelsolin (Gel), important to metabolism, the maintenance of cellular structure and motility as well as platelet development, are differentially upregulated in hAHR-expressing primary mouse hepatocytes (Fig. 4B, Table 2 ). Interestingly, there was a notable difference in fold induction observed between the genes identified in the arrays and the real-time RT-PCR data quantitatively; however, qualitatively, the data are consistent. Also the basal levels of Oxtr and Adi1 in particular 
DISCUSSION
The hAHR and mAHR b differ in amino acid sequence identity at residue A375V within the N-terminal ligand-binding domains of both receptors. This small difference, however, has previously been shown to be responsible for contrasts in the relative affinities of the mAHR b and hAHR for the ligand TCDD. This amino acid residue is found in the middle of the ligand-binding pocket in models of the AHR ligand-binding domain (Denison et al., 2002; Poland et al., 1994) . The mAHR b has a higher relative binding affinity for TCDD compared to the hAHR, whereas the hAHR has a greater relative binding affinity for indirubin compared to the mAHR Ramadoss and Perdew, 2004) . Indeed, hAHR and mAHR b differences in ligand selectivity may be indicative of contrasting functional roles each receptor may have evolved to perform in response to endogenous or exogenous AHR-ligand activation.
The contribution of receptor structural divergence to interspecies differences in receptor activity is not without precedence. Structural divergence between human and mouse peroxisome proliferator activated receptor (PPAR)-a was shown to result in differences in susceptibility to PPAR-a ligandinduced toxicity. In contrast to inbred mice, transgenic mice expressing human PPAR-a were shown to be resistant to fibrateinduced hepatomegaly and liver cancer. This appears to be at least in part due to the differential modulation of genes involved in cellular growth regulation (Cheung et al., 2004) . Also, the constitutive androstane receptor (CAR) ligand, meclizine, was shown to be an agonist and an inverse agonist for the structurally divergent mouse CAR and human CAR, respectively (Huang et al., 2004) . Even the subtle two amino acid residue divergence between human and mouse farnesoid-X-receptor amino acid sequences were shown to be responsible for the contrasting differences in human and mouse bile acid metabolism (Cui et al., 2002) . We also previously showed that the hAHR and mAHR b can differentially recruit LXXLL coactivator-binding motifs, possibly due to differences in the amino acid sequences of the C-terminal TADs of each receptor (Flaveny et al., 2008) . Other previously published studies involving humanized AHR mice have shown that the hAHR responds differently to TCDDinduced activation in vivo (Moriguchi et al., 2003) . Therefore, we postulated that the degree of variation exhibited at the Cterminal domain between the mAHR b and hAHR may lead to differential regulation of gene expression by the human and mouse AHR.
Recent research involving interspecies comparison of DNA microarray data obtained from rat and human hepatocytes treated with TCDD and PCB 126 has highlighted the toxicogenomic differences between rat and human AHR activity (Carlson et al., 2009) . However in this and other studies aimed at comparing of AHR activity across species, the results obtained are limited by the need to identify human gene orthologs. The process of finding human gene orthologs is complicated by the fact that only 37% of rat/mouse genes that possess putative DREs have a known human ortholog (Sun et al., 2004) . The need to search for human/rodent orthologs, which is required to compare TCDD-induced expression profiles across different species, is avoided through the experimental approach employed here. Also, in most cases, rodent and human primary cells require, and thus are exposed to different culture conditions or are derived using distinct processes, both factors that may unpredictably affect interspecies comparisons of DNA microarray-based expression profiles. Also, interspecies comparison of AHR-mediated gene regulation often utilizes transformed human and mouse cell types of mixed or dissimilar origins and thus may be difficult to accurately compare. In this study, we aimed to identify toxicogenomic differences between the mAHR and hAHR activity in response to TCDD treatment. Therefore, in order to more accurately test this hypothesis, we deduced that the hAHR and mAHR b activity can be more precisely compared when expressed in the same cell types that are cultured under identical conditions. Thus, we chose to specifically express the human AHR in hepatocytes on an Ahr fx/fx /Cre alb conditional knockout background . Within these mice, mAHR d expression is replaced by the hAHR only in hepatocytes. In this study, the activity of both receptors within hepatocytes derived from mice with similar genetic backgrounds (C57BL/6J) and exposed to the same hepatocyte Alb ) originating from hepatocytes isolated from one mouse each. RNA samples were generated using a new batch of control-and TCDD-treated hepatocytes that were generated independently of the hepatocytes RNA samples subjected to microarray analysis. For all experiments, total RNA, isolated from hepatocytes, was converted to cDNA and gene expression was quantified using the cognate primers (Supplementary table 1) . Real-time RT-PCR data were analyzed using two-way ANOVA and Bonferroni posttests, and p values < 0.05 were considered statistically significant. *p < 0.05, **p < 0.01, and ***p < 0.001. Alb mice used in this study were not sufficiently backcrossed to be considered fully congenic, the differences in the genetic background of the mice used may have influenced the results obtained. However, it is unlikely that the differential regulation observed herein is due primarily to disparities in the genetic background of the mice used in this study. In addition, the difference in mAHR b and hAHR affinity for TCDD is one potential limitation to the methodology used here to compare the human and mouse AHR. We first considered attempting to address this in part through comparison of the hAHR with the low-affinity mAHR d that is expressed in Ahr fx/fx mice. The difference in relative ligand affinity between the mAHR d and hAHR for TCDD has been estimated to be twofold (Ramadoss and Perdew, 2004) . However, AHR Ttr and Ahr fx/fx mice did not display comparable levels of AHR expression in the liver. Therefore, to avoid introducing further uncertainty associated with differences in receptor protein levels, the mAHR b allele, which was expressed at similar levels to the hAHR, was utilized. Also to overcome the difference between mAHR b and hAHR receptor affinity, a saturating dose of TCDD was used that yielded a similar level of Cyp1a1 induction in hepatocytes for both the mAHR b and the hAHR. However, human and mouse hepatocytes may also differentially express coregulators, which may also contribute to observable differences in hAHR-and mAHR b -mediated gene regulation as well. Additionally, mouse and human coregulators may be structurally divergent, and as a result, the hAHR may interact differentially with mouse coregulators compared to the mAHR b . Moreover, the mAHR b and hAHR differentially interact with LXXLL coactivator motifs and therefore may potentially bind selectively to different coactivators (Flaveny et al., 2008) . As a result, the observed differential gene regulation displayed by the hAHR and mAHR b may have been influenced by interspecies differences in coregulator expression, recruitment, or receptor/coregulator interactions. Nonetheless, in this study, our findings demonstrate that the mAHR b and hAHR are capable of regulating distinct genes in hepatocytes when both receptors are maximally activated by TCDD.
Interestingly, the differences in fold induction observed between the genes identified in the arrays and the real-time RT-PCR data quantitatively differ. Differences between microarray and RT-PCR analysis in terms of the mechanism of detection of expression and disparities in sensitivity that exist between the two techniques may be partially responsible for the differences in fold induction observed. Nonetheless, the data are intended to emphasize distinct qualitative interspecies differences in receptor activity on an identical cellular background, which is consistent across both the realtime and the microarray data presented. In this key aspect, this report provides data that are qualitatively consistent. Also the basal levels of the Oxtr and Adi1, identified to be differentially regulated (Fig. 4) , differed between mAHR band hAHR-expressing hepatocytes. This observed difference in basal expression may be due to a myriad of underlying reasons that may possibly be AHR dependent. In particular, this observation does hint at possible differences in the regulatory activity of the unliganded hAHR and mAHR b . Interestingly, comparisons of DNA microarray expression data from vehicle-treated Ahr b/b and AHR Ttr hepatocytes revealed no significant differences in the basal levels of genes expressed in both hepatocyte genotypes (data not shown). Therefore, this study provides supporting evidence that the structural differences that the hAHR and mAHR exhibit may contribute to distinct biological hAHR-and mAHR-regulated gene expression in hepatocytes. It is possible that this study may be highlighting differences in gene regulation that potentially underpin interspecies differences in receptor physiological roles. But identifying definite differences in mouse and human endogenous or toxicological function is beyond the scope of this study and should be the subject of future research. Future studies therefore should focus on potential differences in the endogenous and toxicologically relevant roles of the hAHR and mAHR in development, immune response, cancer, and reproduction by generating transgenic mice that express the hAHR in various tissues.
The estimation of human toxicological risk for xenobiotic AHR ligands depends on the accuracy of inbred rodents as model systems from which to extrapolate the possible consequences of human exposure to toxic AHR activators. It is cogent and necessary to continually improve on the model systems used to estimate human risk in order to develop a scientifically sound understanding of the caveats and limitations of these models. This investigation identifies an additional challenge to the accuracy of the current approach of extrapolating toxicological data from high-affinity/sensitive mAHR b expressing mouse strains employed to estimate human health risk associated with exposure to AHR ligands, such as TCDD. In this study, we showed that the hAHR and mAHR b can differentially regulate gene expression and thus highlighted another limitation of using data from nontransgenic model systems to predict toxicological consequences of human exposure. These findings also illustrate the importance of transgenic humanized mouse model systems such as the AHR Ttr mouse utilized in this investigation to the scientific endeavor of accurately understanding the possible threats that AHR ligand exposure poses to humans. 
